Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX + Adjuvant Chemoradiotherapy in Resected Pancreatic Cancer
NCT00084383Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2002
- Primary completion
- Dec 2005
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GVAX pancreatic cancer vaccine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Overall Survival at 2 years and Disease-free Survival at 2 years. Started Jan 2002; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00084383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084383.